Abstract:Chimeric antigen receptor T cell (CAR-T) therapy is a late-model of immune cell therapy that has been shown to be effective in refractory/recurrent B-cell leukemia and lymphoma. Compared with the traditional anti-tumor methods, CAR-T cell therapy has the advantages of higher specificity, stronger lethality and longer-lasting efficacy. Although CAR-T cells have made significant progress in the treatment of hematologic malignancies, diverse difficulties remain in the treatment of solid tumors, including immune escape due to tumor antigen heterogeneity, preventing entry or limiting the persistence of CAR-T cells by physical or cytokine barriers and along with other immunosuppressive molecule and cells in the tumor microenvironment (TME). Otherwise, the intracellular signaling of CAR also impact on CAR-T cells persistence. Appropriate modification of intracellular costimulatory molecular signal in the structure of CAR or coexpression of CAR and cytokines can provide a way to enhance CAR-T cells activity. Additionally, CAR-T cells dysfunction due to T cell exhaustion is associated with multi-factors, especially transcription factors, such as c-Jun, NR4A. Engineering CAR-T cells to coexpress or knockout transcription factors in favor of T<sub>CM</sub> memory CAR-T cells differentiation was proved to prolonged the survival of CAR-T cells. Finally, combination of CAR-T cells with oncolytic viruses, nanoparticles or immune checkpoint inhibitors provides an effective measure to improve CAR-T cells function. Here, we discuss all of these advances and challenges and review promising strategies for treating solid tumors. In particular, we also highlight that CAR-T cells have enormous potential to be used in combination with other immunotherapies.

Prospects and challenges of CAR-T cell therapy combined with ICIs

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Challenges and strategies in relation to effective CAR-T cell immunotherapy for solid tumors

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities.

CAR-T therapy and targeted treatments: Emerging combination strategies in solid tumors

Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors

Current progress in CAR-T cell therapy for tumor treatment

Challenges and innovations in CAR-T cell therapy: a comprehensive analysis

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Current Progress in CAR-T Cell Therapy for Solid Tumors

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors

CAR-T cell combination therapies in hematologic malignancies

The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors

Bright future or blind alley? CAR-T cell therapy for solid tumors

A long way to the battlefront: CAR T cell therapy against solid cancers.

Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances

Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies

Challenges and interventions of chimeric antigen receptor-T cell therapy in solid tumors

Prospects and challenges for use of CAR T cell therapies in solid tumors